All Stories

  1. HIV treatment outcomes after 10 years on ART in the TREAT Asia Observational Database (TAHOD) and Australian HIV Observational Database (AHOD)
  2. The use of long-term antibiotics for suppression of bacterial infections
  3. The burden of skin and soft tissue, bone and joint infections in an Australian cohort of people who inject drugs
  4. Changes in atherosclerotic cardiovascular disease risk over time among people living with HIV
  5. Impact of COVID-19 on people with non-functioning spleens in Australia
  6. Addressing atherosclerotic cardiovascular disease risk in persons with HIV
  7. More evidence for inequitable COVID-19 outcomes in people with HIV
  8. Primary cardiovascular prevention in people with HIV: what's the score?
  9. Successful expanded clinic network collaboration and patient tracing for retention in HIV care
  10. Human herpes virus 8-related illness: still with us
  11. Long term antibiotic prescribing in the community: 6 years of Australian national data
  12. New diagnosis of HIV with Cryptococcus neoformans infection presenting as a pleural syndrome
  13. The impact of the COVID-19 pandemic on people with HIV in Victoria, Australia: 1 year later
  14. Successful Expanded Clinic Network Collaboration and Patient Tracing for Retention in HIV Care
  15. Integrating Hepatitis C Virus Treatment Programs Within Community Mental Health
  16. Outcomes in Medicare‐ineligible people living with human immunodeficiency virus in a large healthcare network in Melbourne 2004–2019
  17. Congenital asplenia study: clinical and laboratory characterisation of adults with congenital asplenia
  18. Reductions in Antibiotic Prescribing in Australia During the SARS-CoV-2 Pandemic: National Prescribing Data
  19. When pandemics collide: measuring the impact of coronavirus disease 2019 on people with HIV
  20. Long-Term Outcomes in Patients on Life-Long Antibiotics: A Five-Year Cohort Study
  21. Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV
  22. Physical function limitation among gay and bisexual men aged ≥55years with and without HIV: findings from the Australian Positive and Peers Longevity Evaluation Study (APPLES)
  23. Hepatitis C virus in people with serious mental illness: An analysis of the care cascade at a tertiary health service with a pilot ‘identify and treat’ strategy
  24. SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study
  25. COVID ‐19: looking backward
  26. HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults
  27. Underutilised human immunodeficiency virus testing in the setting of invasive pneumococcal disease
  28. The Clinical and Financial Burden of Spinal Infections in People who Inject Drugs
  29. IgG4-related disease masquerading as a fungating groin lesion in a patient with HIV and incomplete immune reconstitution
  30. The impact of the COVID-19 pandemic on people living with HIV in Victoria, Australia
  31. A novel case of bilateral tubo-ovarian abscesses attributed to Ruminococcus gnavus without gastrointestinal involvement
  32. Routine testing for hyposplenism in a lupus clinic diagnoses; new cases and opportunities for intervention
  33. Breaking the fourth wall: Integrating quality into HIV care
  34. Trends in practice: attitudes and challenges in the diagnosis, treatment and management of HIV infection in Australia
  35. Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study
  36. Age-related clonal haematopoiesis is more prevalent in older adults with HIV: the ARCHIVE study
  37. Case Report: Japanese Encephalitis Associated with Chorioretinitis after Short-Term Travel to Bali, Indonesia
  38. Acceptability of injectable anti-retroviral therapy in Australian travellers with HIV
  39. Coronavirus disease 2019 (COVID‐19): not one epidemic but four
  40. Platelet phenotype and function in the absence of splenic sequestration (Review)
  41. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single‐tablet regimen in the expanding spectrum of fixed‐dose combination therapy for HIV
  42. The burden of infective endocarditis in an Australian cohort of people who inject drugs
  43. Intermittent negative blood cultures in Staphylococcus aureus bacteremia; A retrospective study of 1071 episodes
  44. Surveillance of life-long antibiotics—A cross-sectional cohort study assessing patient attitudes and understanding of long-term antibiotic consumption
  45. HIV presenting as AIDS in previously undiagnosed tourists in a low-prevalence setting
  46. Review of HIV testing recommendations in Australian specialty guidelines for HIV indicator conditions: a missed opportunity for recommending testing?
  47. Post-splenectomy sepsis: preventative strategies, challenges, and solutions
  48. Prevalence and distribution of functional splenic tissue after splenectomy
  49. Implementation of “Treat‐all” at adult HIV care and treatment sites in the Global Ie DEA Consortium: results from the Site Assessment Survey
  50. Healthy, safe and effective international medical student electives: a systematic review and recommendations for program coordinators
  51. Infectious diseases physician attitudes to long-term antibiotic use
  52. Response to letter to editor regarding Lin et al ‘Prevalence of HIV indicator conditions in late presenting patients with HIV: a missed opportunity for diagnosis?’
  53. Management of gonorrhoea in a hospital network: are we following best practice?
  54. Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT Asia HIV Observational Database (TAHOD) and Australian HIV Observational Database (AHOD) of IeDEA Asia-Pacific
  55. Human immunodeficiency virus-infected young people in Australia: data from the Australian HIV Observational Database
  56. Cardiovascular disease and diabetes in HIV-positive and HIV-negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study
  57. Prevalence of HIV indicator conditions in late presenting patients with HIV: a missed opportunity for diagnosis?
  58. Initial modelling and updates on cost effectiveness from the first 10 years of a spleen registry
  59. Are Bone Disease and Cardiovascular Disease Risk Correlated in an HIV Cohort?
  60. Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individuals
  61. Chronic kidney disease in Australian Human Immunodeficiency Virus-infected patients: Analysis of the Australian HIV Observational Database
  62. Impact of a spleen registry on optimal post-splenectomy vaccination and care
  63. HIV in practice: current approaches and challenges in the diagnosis, treatment and management of HIV infection in Australia
  64. Life-long antimicrobial therapy: where is the evidence?
  65. Selected state of the art research in internal medicine, 2017
  66. Levels of regulatory B cells do not predict serological responses to hepatitis B vaccine
  67. Physician testing for HIV in patients treated with tenofovir disoproxil fumarate and lamivudine monotherapy for hepatitis B virus
  68. Increasing Prevalence and Risk of Chronic Kidney Disease in Human Immunodeficiency Virus–Infected Individuals: Changing Demographics Over a 6-Year Period
  69. Understanding of the significance and health implications of asplenia in a cohort of patients with haemaglobinopathy: possible benefits of a spleen registry
  70. Cryptococcal/CSF ventricular levels on MRI brain in a man with AIDS
  71. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study
  72. High rates of potentially infectious exposures between immunocompromised patients and their companion animals: an unmet need for education
  73. The impact of changes in HIV management guidelines on time to treatment initiation in Australia
  74. Integrase-resistant HIV in an antiretroviral-naive patient in Australia
  75. Surveillance of life-long antibiotics: a review of antibiotic prescribing practices in an Australian Healthcare Network
  76. Cryptococcemia in primary HIV infection
  77. Isn't it time to talk about antiretroviral stewardship?
  78. Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 4...
  79. Tenofovir Therapy for Hepatitis B May Be Commonly Prescribed Without HIV Testing
  80. Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study
  81. Treatment and disease outcomes of migrants from low- and middle-income countries in the Australian HIV Observational Database cohort
  82. Low rates of endocarditis in healthcare-associated Staphylococcus aureus bacteremia suggest that echocardiography might not always be required
  83. A history of infection with varicella is strongly predictive of the presence of varicella-zoster virus antibodies in a heterogenous Australian HIV cohort
  84. Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)
  85. Acute HIV infection presenting as erythema multiforme in a 45-year-old heterosexual man
  86. Caught in the act… a case of fulminant amoebic colitis
  87. International travel in the immunocompromised patient: a cross-sectional survey of travel advice in 254 consecutive patients
  88. Clinic Network Collaboration and Patient Tracing to Maximize Retention in HIV Care
  89. Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in Australia
  90. Latent infection in HIV-positive refugees and other immigrants in Australia
  91. An analysis of the thromboembolic outcomes of 2472 splenectomized individuals
  92. Mycobacterium haemophilumbone and joint infection in HIV/AIDS: case report and literature review
  93. Correction: Recent trends in early stage response to combination antiretroviral therapy in Australia
  94. Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men
  95. Acanthamoeba Encephalitis: Isolation of Genotype T1 in Mycobacterial Liquid Culture Medium
  96. HIV and aging: insights from the Asia Pacific HIV Observational Database (APHOD)
  97. What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore
  98. Macrophage migration inhibitory factor
  99. Determinants of Viremia Copy-Years in People With HIV/AIDS After Initiation of Antiretroviral Therapy
  100. The Significance of HIV ‘Blips’ in Resource-Limited Settings: Is It the Same? Analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD)
  101. The significance of low-level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD)
  102. Recent trends in early stage response to combination antiretroviral therapy in Australia
  103. C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals
  104. Antiretroviral Treatment Interruption and Loss to Follow-Up in Two HIV Cohorts in Australia and Asia: Implications for ‘Test and Treat’ Prevention Strategy
  105. The inside story. Physicians’ views on digital ano-rectal examination for anal cancer screening of HIV positive men who have sex with men
  106. HIV Replication Alters the Composition of Extrinsic Pathway Coagulation Factors and Increases Thrombin Generation
  107. The two-edged sword: vasculitis associated with HIV and hepatitis C coinfection
  108. Incidence and risk factors for acute respiratory illnesses and influenza virus infections in Australian travellers to Asia
  109. Low Risk of Japanese Encephalitis in Short‐Term Australian Travelers to Asia
  110. Determining research priorities for clinician-initiated trials in infectious diseases
  111. Vitamin d deficiency impacts on expression of toll-like receptor-2 and cytokine profile: a pilot study
  112. Shooting At the DARC: Potential Issues with Species-Specific Antimalarials
  113. Visiting friends and relatives may be a risk for non-adherence for HIV-positive travellers
  114. Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia
  115. Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD)
  116. Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
  117. Acute Mediastinal Melioidosis: Diagnosis By Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
  118. Splenectomy sequelae: an analysis of infectious outcomes among adults in Victoria
  119. New HIV diagnosis after occupational exposure screening: the importance of reporting needlestick injuries
  120. Incidence and seroprevalence of dengue virus infections in Australian travellers to Asia
  121. CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts
  122. Rat bite fever as a presenting illness in a patient with AIDS
  123. Splenectomy Associated Changes in IgM Memory B Cells in an Adult Spleen Registry Cohort
  124. Low CD4 Count Is Associated With an Increased Risk of Fragility Fracture in HIV-Infected Patients
  125. Comment on: The DART Trial: 'The Doctor's Dilemma' revisited
  126. The Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHOD
  127. N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients
  128. Trends in detectable viral load by calendar year in the Australian HIV observational database
  129. Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections
  130. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial
  131. The Influence of Splenectomy on the Infectious Complications and Outcomes of people With HIV: Marked, Sustained Elevation in Risk of Severe Infection With Bacteria Including Streptococcus pneumoniae
  132. Cardiac computed tomography in endocarditis
  133. Autoimmune haemolytic anaemia: an unusual presentation of HIV seroconversion disease
  134. CORRIGENDUM
  135. Re: Published article - patient knowledge of the risks of post-splenectomy sepsisANZ J. Surg.2008; 78: 867-70
  136. Duffy antigen expression on reticulocytes does not alter following blood loss in an autologous donation model
  137. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management
  138. Duffy Antigen Polymorphisms Do Not Alter Progression of HIV in African Americans in the MACS Cohort
  139. Shedding light on DARC: the role of the Duffy antigen/receptor for chemokines in inflammation, infection and malignancy
  140. HIV infection and high density lipoprotein metabolism
  141. Guidelines for the prevention of sepsis in asplenic and hyposplenic patients
  142. Unrecognised vitamin D deficiency: low concentrations in African migrants with HIV in Australia
  143. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993?2006
  144. Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART
  145. Acute pancreatitis caused by tipranavir/ritonavir-induced hypertriglyceridaemia
  146. Macrolide use and the risk of vascular disease in HIV-infected men in the Multicenter AIDS Cohort Study
  147. Cambodian-born individuals diagnosed with HIV in Victoria: epidemiological findings and health service implications
  148. Cost-effectiveness of a post-splenectomy registry for prevention of sepsis in the asplenic
  149. Occupational exposures experienced by medical students during overseas electives
  150. Rat-bite fever septic arthritis: illustrative case and literature review
  151. ADHERENCE TO GUIDELINES FOR PREVENTION OF POSTSPLENECTOMY SEPSIS. AGE AND SEX ARE RISK FACTORS: A FIVE-YEAR RETROSPECTIVE REVIEW
  152. A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy
  153. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment
  154. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database
  155. Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction
  156. Eosinophilic folliculitis
  157. The Use of Antibiotics as Secondary Prevention for Cardiac Events
  158. Lichenoid drug eruption to tenofovir in an HIV/hepatitis B virus co-infected patient
  159. Chlamydia pneumoniae in HIV-infected patients and controls assessed by a novel whole blood interferon-γ assay, serology and PCR
  160. Clostridium septicum Bacteremia Without Gas Gangrene as a Late Consequence of a Contaminated Wound
  161. Fragility Fractures in HIV-Infected Patients: Need for Better Understanding of Diagnosis and Management
  162. Disseminated Mycobacterium avium-intracellulare Complex (MAC) Infection in the Era of Effective Antiretroviral Therapy
  163. Sequential cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis
  164. Effect of GB Virus C Coinfection on Response to Antiretroviral Treatment in Human Immunodeficiency Virus–Infected Patients
  165. Changing Spectrum of Mortality Due to Human Immunodeficiency Virus: Analysis of 260 Deaths during 1995-1999
  166. Duffy-null promoter heterozygosity reduces DARC expression and abrogates adhesion of theP. vivaxligand required for blood-stage infection
  167. Letter to the Editor
  168. Differential expression of the Duffy antigen receptor for chemokines according to RBC age and FY genotype
  169. Emergence of FY*A null in a Plasmodium vivax -endemic region of Papua New Guinea
  170. Human Immunodeficiency Virus 1 Protease Inhibitors in Clinical Practice
  171. GBV-C/HGV infection in HIV-infected patients
  172. Hepatitis G Virus RNA Is Common in AIDS Patients' Plasma but Is Not Associated With Abnormal Liver Function Tests or Other Clinical Syndromes
  173. Transmissible spongiform encephalopathy and new variantCreutzfeldt-Jakob disease
  174. Piroplasmosis
  175. Postpartum Epidural Abscess Due to Group BStreptococcus
  176. Diffuse alveolar damage following a single administration of a cyclophosphamide containing chemotherapy regimen
  177. CD4 lymphocyte counts in HIV/AIDS patients with intercurrent illness